6 results
10-K
2021 FY
VERV
Verve Therapeutics Inc
14 Mar 22
Annual report
7:04am
company with a track record of partnering and developing LNPs for clinical use. Additionally, our internal team’s expertise in biodegradable LNP … reached their peak outcomes within two weeks of dosing. The major component of the LNP, the ionizable lipid, is designed to be biodegradable
424B4
VERV
Verve Therapeutics Inc
17 Jun 21
Prospectus supplement with pricing info
4:50pm
company with a track record of partnering and developing LNPs for clinical use. Additionally, our internal team’s expertise in biodegradable LNP … , is designed to be biodegradable and to be eliminated from the blood within two weeks, and we observed that it was largely eliminated from the liver, to less
S-1/A
VERV
Verve Therapeutics Inc
14 Jun 21
IPO registration (amended)
6:15am
and developing LNPs for clinical use. Additionally, our internal team’s expertise in biodegradable LNP chemistry, formulation and manufacturing has … their peak outcomes within two weeks of dosing. The major component of the LNP, the ionizable lipid, is designed to be biodegradable and to be eliminated
S-1
VERV
Verve Therapeutics Inc
28 May 21
IPO registration
4:04pm
company with a track record of partnering and developing LNPs for clinical use. Additionally, our internal team’s expertise in biodegradable LNP … to be biodegradable and to be eliminated from the blood within two weeks, and we observed that it was largely eliminated from the liver, to less than
DRS
3p1ii3
16 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next